As few as one in ten people survive pancreatic cancer five years after their diagnosis — making it the most difficult cancer to survive. The survival rate five years after diagnosis is 6-14%, but ...

Fear of nuclear fallout has led to a novel therapeutic approach that could significantly extend the lives of individuals with ...

Recent positive lab confirmation of Smart mRNA functionality is a tremendous milestone for the Company. This marks a ...

Thanks to decades of sustained, predictable federal investments and increases in pancreatic cancer research, the research ...

Ribonucleic acid, commonly known as RNA, is involved in many biological functions, and some, including gene silencing, are utilized to cure diseases. RNA has recently gained attention as a promising ...

Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional ...

Several ASX-listed healthcare companies with low market caps are making strides in tackling cancer,  a leading cause of death ...

Results from a trial of an mRNA vaccine for pancreatic cancer have shown that the vaccine reduces the chance of the cancer ...

The study developed a noninvasive detection method based on serum protease activity, leveraging the increased protease activity in the peripheral blood of patients with PDAC. Researchers screened a ...

Pancreatic cancer is the 10th deadliest form of cancer in the United States, according to the National Cancer Institute.

In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three ...

A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease ...